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Background
Adoptive cell therapy (ACT) of tumor infiltrating lym-
phocytes (TIL) has shown the ability to induce complete
regression of stage IV melanoma. Two challenges asso-
ciated TIL ACT are that (i) T cells are capable of differ-
ent anti-tumor effector functions including cytotoxicity,
cytokine secretion, and homing to target tissues, and
currently no methodologies exist that can inform on all
of these functions for a given (single) cell, and (ii) the
relative contributions of each of these effector functions
to the overall anti-tumor effect remains un-quantified.
Methods
Here, we evaluated a set of four infusion products from
patients treated with TIL ACT: two Complete Respon-
ders (CR) and two patients with Progressive Disease (PD)
with high percentages of CD8+ T cell population and
with established autologous primary tumor cell lines.
Results
Flow cytometry analysis of the tumor reactive TIL
showed no difference in the frequency of TIL secreting
IFN-g or degranulating in response to the autologous
tumor. Utilizing Timelapse Imaging Microscopy In
Nanowell Grids (TIMING), we demonstrate that while
the frequencies of individual TIL participating in killing
of autologous tumor cells is equivalent across the
donors, TIL from CR patients demonstrated a longer
duration of conjugation prior to killing the tumor cell
(CR 211 ± 7 min vs PD 131 ± 5 min). Furthermore,
both in the presence and absence of tumors cells, the
motility of the TIL was significantly higher (CR 4.7 ±
0.2 µm vs PD 2.9 ± 0.1 µm). Multiplexed single-cell
gene-expression profiling of the TIL, classified based on
activated functional states (CD69/CD107a/IFN-g)
demonstrated that the functional classification was not
useful in clustering cells from different donors but
rather, clustering of cells was dictated by the donor
regardless of function. Lastly, we demonstrate that a
core signature of the activated TIL consisting of CD37,
CD44, IL7R, CD28, CD27, IFNGR1, TIM-3, MAPK1 and
MTOR were up-regulated in CR patients and the levels
of TGFB1, BCL2, IL2RG, PDRM1 and IL12RB2 were up-
regulated in PD patients.
Conclusions
In summary, our results demonstrate that single cell
profiling may be useful in determining not only the
transcriptional signatures of TIL with favorable clinical
responses but also uncover simple physical attributes
like basal motility that might serve as a surrogate mar-
ker for activated/functional TIL.
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